| Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy TN Gide, C Quek, AM Menzies, AT Tasker, P Shang, J Holst, J Madore, ... Cancer cell 35 (2), 238-255. e6, 2019 | 662 | 2019 |
| BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact H Rizos, AM Menzies, GM Pupo, MS Carlino, C Fung, J Hyman, LE Haydu, ... Clinical cancer research 20 (7), 1965-1977, 2014 | 571 | 2014 |
| Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma GV Long, C Fung, AM Menzies, GM Pupo, MS Carlino, J Hyman, ... Nature communications 5 (1), 5694, 2014 | 391 | 2014 |
| Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma ES Gray, H Rizos, AL Reid, SC Boyd, MR Pereira, J Lo, V Tembe, ... Oncotarget 6 (39), 42008, 2015 | 347 | 2015 |
| Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ... European journal of cancer 51 (18), 2792-2799, 2015 | 341 | 2015 |
| Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma JH Lee, GV Long, S Boyd, S Lo, AM Menzies, V Tembe, A Guminski, ... Annals of Oncology 28 (5), 1130-1136, 2017 | 315 | 2017 |
| Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy SY Lim, JH Lee, TN Gide, AM Menzies, A Guminski, MS Carlino, EJ Breen, ... Clinical Cancer Research 25 (5), 1557-1563, 2019 | 302 | 2019 |
| Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis TJ Parmenter, M Kleinschmidt, KM Kinross, ST Bond, J Li, MR Kaadige, ... Cancer discovery 4 (4), 423-433, 2014 | 292 | 2014 |
| Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies JH Lee, GV Long, AM Menzies, S Lo, A Guminski, K Whitbourne, ... JAMA oncology 4 (5), 717-721, 2018 | 285 | 2018 |
| Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB K Gowrishankar, D Gunatilake, SJ Gallagher, J Tiffen, H Rizos, P Hersey PloS one 10 (4), e0123410, 2015 | 246 | 2015 |
| A melanoma-associated germline mutation in exon 1β inactivates p14ARF H Rizos, S Puig, C Badenas, J Malvehy, AP Darmanian, L Jiménez, ... Oncogene 20 (39), 5543-5547, 2001 | 227 | 2001 |
| Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? SJ Welsh, H Rizos, RA Scolyer, GV Long European journal of cancer 62, 76-85, 2016 | 224 | 2016 |
| WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors JN Anastas, RM Kulikauskas, T Tamir, H Rizos, GV Long, EM Von Euw, ... The Journal of clinical investigation 124 (7), 2877-2890, 2014 | 217 | 2014 |
| Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition JH Lee, E Shklovskaya, SY Lim, MS Carlino, AM Menzies, A Stewart, ... Nature communications 11 (1), 1897, 2020 | 208 | 2020 |
| Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium RN Amaria, AM Menzies, EM Burton, RA Scolyer, MT Tetzlaff, ... The Lancet Oncology 20 (7), e378-e389, 2019 | 202 | 2019 |
| Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma YNV Gopal, H Rizos, G Chen, W Deng, DT Frederick, ZA Cooper, ... Cancer research 74 (23), 7037-7047, 2014 | 193 | 2014 |
| Differentiation of cucumber mosaic virus isolates using the polymerase chain reaction H Rizos, LV Gunn, RD Pares, MR Gillings Journal of General Virology 73 (8), 2099-2103, 1992 | 159 | 1992 |
| Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial GV Long, RPM Saw, S Lo, OE Nieweg, KF Shannon, M Gonzalez, ... The Lancet Oncology 20 (7), 961-971, 2019 | 157 | 2019 |
| Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma SY Lim, AM Menzies, H Rizos Cancer 123 (S11), 2118-2129, 2017 | 154 | 2017 |
| Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF H Rizos, AP Darmanian, EA Holland, GJ Mann, RF Kefford Journal of Biological Chemistry 276 (44), 41424-41434, 2001 | 149 | 2001 |
Richard KeffordMacquarie University在 mq.edu.au 的电子邮件经过验证
